

Vanessa Roldan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4763098/publications.pdf>

Version: 2024-02-01

204
papers

8,983
citations

70961

41
h-index

46693

89
g-index

219
all docs

219
docs citations

219
times ranked

9613
citing authors

#	ARTICLE	IF	CITATIONS
1	The Atrial Fibrillation Better Care (ABC) Pathway and Clinical Outcomes in Patients with Atrial Fibrillation: the Prospective Murcia AF Project Phase II Cohort. <i>Journal of General Internal Medicine</i> , 2023, 38, 315-323.	1.3	2
2	Number needed to treat for net effect of anticoagulation in atrial fibrillation: Real-world vs clinical-trial evidence. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 282-289.	1.1	8
3	Characteristics and management of patients with stroke and major hemorrhagic episodes with atrial fibrillation under vitamin K antagonist therapy. EVENTHO study. <i>Medicina Clínica</i> , 2022, , .	0.3	0
4	Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society. <i>Europace</i> , 2022, 24, 1844-1871.	0.7	11
5	Relation of the "Atrial Fibrillation Better Care (ABC) Pathway"™ to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists. <i>Journal of Personalized Medicine</i> , 2022, 12, 487.	1.1	4
6	Prediction of ischemic stroke in different populations: a comparison of absolute stroke risk and CHA2DS2-VASc in real-world and clinical trial patients. <i>European Journal of Internal Medicine</i> , 2022, 98, 122-124.	1.0	1
7	Relationship between temporal rhythm-based classification of atrial fibrillation and stroke: real-world vs. clinical trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, , 1.	1.0	0
8	Diagnostic and therapeutic potential of miRNAs in cardiovascular disease: a clinical reality?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2022, , .	0.4	0
9	Outcomes in VKA-treated patients with atrial fibrillation and chronic kidney disease: Clinical trials vs "real-world"™. <i>International Journal of Clinical Practice</i> , 2021, 75, e13888.	0.8	1
10	Gut Microbiota and the Quality of Oral Anticoagulation in Vitamin K Antagonists Users: A Review of Potential Implications. <i>Journal of Clinical Medicine</i> , 2021, 10, 715.	1.0	9
11	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. <i>Europace</i> , 2021, 23, 1612-1676.	0.7	494
12	Prediction of Residual Stroke Risk in Anticoagulated Patients with Atrial Fibrillation: mCARS. <i>Journal of Clinical Medicine</i> , 2021, 10, 3357.	1.0	4
13	Relationship between multimorbidity and outcomes in atrial fibrillation. <i>Experimental Gerontology</i> , 2021, 153, 111482.	1.2	16
14	Anticoagulant therapy in patients with congenital FXI deficiency. <i>Blood Advances</i> , 2021, 5, 4083-4086.	2.5	1
15	Non-vitamin K Antagonist Oral Anticoagulants and Drug-Food Interactions: Implications for Clinical Practice and Potential Role of Probiotics and Prebiotics. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 787235.	1.1	4
16	Treatment strategies for patients with atrial fibrillation and anticoagulant-associated intracranial hemorrhage: an overview of the pharmacotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1867-1881.	0.9	3
17	Pilot Study on the Role of Circulating miRNAs for the Improvement of the Predictive Ability of the 2MACE Score in Patients with Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2020, 9, 3645.	1.0	11
18	Factor XI, much more than an innocent observer. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3172-3173.	1.9	1

#	ARTICLE	IF	CITATIONS
19	A nurse-led atrial fibrillation clinic: Impact on anticoagulation therapy and clinical outcomes. <i>International Journal of Clinical Practice</i> , 2020, 74, e13634.	0.8	13
20	Factor XII in PMM2-CDG patients: role of N-glycosylation in the secretion and function of the first element of the contact pathway. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 280.	1.2	9
21	Particulate Matter and Temperature: Increased Risk of Adverse Clinical Outcomes in Patients With Atrial Fibrillation. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2360-2369.	1.4	8
22	ALG12-CDG: An unusual patient without intellectual disability and facial dysmorphism, and with a novel variant. <i>Molecular Genetics & Genomic Medicine</i> , 2020, 8, e1304.	0.6	12
23	Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1200-1207.	1.8	41
24	Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 749-757.	0.4	38
25	Influence of sex on long-term prognosis in patients with atrial fibrillation treated with oral anticoagulants. Results from the prospective, nationwide FANTASIA study. <i>European Journal of Internal Medicine</i> , 2020, 78, 63-68.	1.0	3
26	Influence of the matrix type over the concentration of GDF-15. <i>Journal of Investigative Medicine</i> , 2020, 68, 1402-1404.	0.7	0
27	Identification of 58 Mutations (26 Novel) in 94 of 109 Symptomatic Spanish Proband with Protein C Deficiency. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1409-1418.	1.8	8
28	The Use of Biomarkers in Clinical Management Guidelines: A Critical Appraisal. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1901-1919.	1.8	57
29	Refining Stroke and Bleeding Prediction in Atrial Fibrillation by Adding Consecutive Biomarkers to Clinical Risk Scores. <i>Stroke</i> , 2019, 50, 1372-1379.	1.0	48
30	Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation. <i>BMJ Open</i> , 2019, 9, e033712.	0.8	3
31	Efficacy and safety of peri-procedural bridging therapy with low molecular weight heparin in atrial fibrillation patients under vitamin K antagonists. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2019, 112, 183-188.	0.2	3
32	Effect of <i>CYP4F2</i> , <i>VKORC1</i> , and <i>CYP2C9</i> in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1477-1491.	2.3	23
33	Riesgo embólico, riesgo isquémico y riesgo hemorrágico. <i>Revista Espanola De Cardiologia Suplementos</i> , 2019, 18, 3-8.	0.2	0
34	Assessment of two contact activation reagents for the diagnosis of congenital factor XI deficiency. <i>Thrombosis Research</i> , 2018, 163, 64-70.	0.8	12
35	Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12929.	1.7	5
36	Optimizing Vitamin K Antagonist Treatment in Patients with Mechanical Heart Valve Prosthesis. <i>Thrombosis and Haemostasis</i> , 2018, 118, 806-807.	1.8	1

#	ARTICLE	IF	CITATIONS
37	Antiplatelet therapy combined with acenocoumarol in relation to major bleeding, ischaemic stroke and mortality. <i>International Journal of Clinical Practice</i> , 2018, 72, e13069.	0.8	4
38	MiR-146a Regulates Neutrophil Extracellular Trap Formation That Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 892-902.	1.1	66
39	Quality of oral anticoagulation with vitamin K antagonists in "real-world"™ patients with atrial fibrillation: a report from the prospective multicentre FANTASIA registry. <i>Europace</i> , 2018, 20, 1435-1441.	0.7	39
40	Relation of Renal Dysfunction to Quality of Anticoagulation Control in Patients with Atrial Fibrillation: The FANTASIA Registry. <i>Thrombosis and Haemostasis</i> , 2018, 118, 279-287.	1.8	17
41	Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol. <i>Clinical Therapeutics</i> , 2018, 40, 114-122.	1.1	21
42	A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the "Real-World" vs Clinical Trials. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1065-1073.	1.4	28
43	Soluble Fibrin Monomer Complex and Prediction of Cardiovascular Events in Atrial Fibrillation: The Observational Murcia Atrial Fibrillation Project. <i>Journal of General Internal Medicine</i> , 2018, 33, 847-854.	1.3	14
44	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. <i>Europace</i> , 2018, 20, 1231-1242.	0.7	194
45	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>European Heart Journal</i> , 2018, 39, 1330-1393.	1.0	1,576
46	Enhancing the "real world"™ prediction of cardiovascular events and major bleeding with the CHA ₂ DS ₂ -VASc and HAS-BLED scores using multiple biomarkers. <i>Annals of Medicine</i> , 2018, 50, 26-34.	1.5	22
47	Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in "real-world"™ atrial fibrillation patients: A comparison with optimally acenocoumarol anticoagulated patients. <i>International Journal of Cardiology</i> , 2018, 254, 125-131.	0.8	18
48	Prediction of long-term net clinical outcomes using the TIMI-AF score: Comparison with CHA ₂ DS ₂ -VASc and HAS-BLED. <i>American Heart Journal</i> , 2018, 197, 27-34.	1.2	8
49	Increasing therapy-related myeloid neoplasms in multiple myeloma. <i>European Journal of Clinical Investigation</i> , 2018, 49, e13050.	1.7	12
50	Oral anticoagulation and comorbidities; too many details for clinical practice?. <i>International Journal of Cardiology</i> , 2018, 264, 93-94.	0.8	1
51	Comparison of the 2MACE and TIMI-AF Scores for Composite Clinical Outcomes in Anticoagulated Atrial Fibrillation Patients. <i>Circulation Journal</i> , 2018, 82, 1286-1292.	0.7	4
52	Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World"™ in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2018, 122, 785-792.	0.7	12
53	Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEL, SECOT and AEU. <i>Revista Espanola De Cardiologia (English)</i> TJ ETQq1 1 0.784314 rgBT	0.4	35
54	miR-146a deficiency in hematopoietic cells is not involved in the development of atherosclerosis. <i>PLoS ONE</i> , 2018, 13, e0198932.	1.1	16

#	ARTICLE	IF	CITATIONS
55	Intra-ventricular thrombus resolution after anticoagulation therapy with rivaroxaban in patient with poor anticoagulation quality. <i>Cardiology Journal</i> , 2018, 25, 151-154.	0.5	4
56	Comentarios a la guÃa ESC 2016 sobre el diagnÃstico y tratamiento de la fibrilaciÃn auricular. <i>Revista Espanola De Cardiologia</i> , 2017, 70, 2-8.	0.6	11
57	Does von Willebrand factor improve the predictive ability of current risk stratification scores in patients with atrial fibrillation?. <i>Scientific Reports</i> , 2017, 7, 41565.	1.6	31
58	Regulation of TFPÎ± expression by miR-27a/b-3p in human endothelial cells under normal conditions and in response to androgens. <i>Scientific Reports</i> , 2017, 7, 43500.	1.6	20
59	Comments on the 2016 ESC Guidelines for the Management of Atrial Fibrillation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 2-8.	0.4	5
60	Evaluation of HAS-BLED and ORBIT Bleeding Risk Scores in Nonvalvular Atrial Fibrillation Patients Receiving Oral Anticoagulants. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 132-133.	0.4	0
61	Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2017, 120, 2176-2181.	0.7	19
62	Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation. <i>Scientific Reports</i> , 2017, 7, 12066.	1.6	16
63	Longâ€Term Stroke Risk Prediction in Patients With Atrial Fibrillation: Comparison of the ABCâ€Stroke and CHA ₂ DS ₂ â€VASc Scores. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	42
64	Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1051-1062.	1.0	24
65	Applicability of the modified CHA 2 DS 2 -VASc score for stroke risk stratification in Caucasian atrial fibrillation patients. <i>European Journal of Internal Medicine</i> , 2017, 38, e21-e22.	1.0	5
66	Factors Affecting the Quality of Anticoagulation With Vitamin K Antagonists in Venous Thromboembolism Patients. <i>Biological Research for Nursing</i> , 2017, 19, 198-205.	1.0	1
67	Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1448-1454.	1.8	74
68	Assessing Bleeding Risk in Atrial Fibrillation Patients: Comparing a Bleeding Risk Score Based Only on Modifiable Bleeding Risk Factors against the HAS-BLED Score. The AMADEUS Trial. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2261-2266.	1.8	51
69	Predicting bleeding risk after coronary surgery: Letâ€™s focus on modifiable risk factors and simple, practical decision making. <i>Thrombosis and Haemostasis</i> , 2017, 117, 647-649.	1.8	5
70	Long-term bleeding risk prediction in â€real worldâ€™ patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1848-1858.	1.8	56
71	Genotype-guided therapy improves initial acenocoumarol dosing. <i>Thrombosis and Haemostasis</i> , 2016, 115, 117-125.	1.8	10
72	MIRNA-Based Regulation of Hemostatic Factors through Hepatic Nuclear Factor-4 Alpha. <i>PLoS ONE</i> , 2016, 11, e0154751.	1.1	19

#	ARTICLE	IF	CITATIONS
73	Strategies for prediction and early detection of atrial fibrillation: present and future. <i>Europace</i> , 2016, 19, euw131.	0.7	3
74	En el camino de un mejor uso de los anticoagulantes en la fibrilaci3n auricular no valvular. Propuesta de modificaci3n del posicionamiento terap3utico UT/V4/23122013. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 551-553.	0.6	28
75	On the Way to a Better Use of Anticoagulants in Nonvalvular Atrial Fibrillation. Proposed Amendment to the Therapeutic Positioning Report UT/V4/23122013. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 551-553.	0.4	10
76	The HAS-BLED score predicts long-term major bleeding and death in anticoagulated non-valvular atrial fibrillation patients undergoing electrical cardioversion. <i>International Journal of Cardiology</i> , 2016, 217, 42-48.	0.8	6
77	New Role of Biomarkers in Atrial Fibrillation. , 2016, , 507-539.		0
78	Long-Term Predictors of Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Undergoing Electrical Cardioversion. <i>Circulation Journal</i> , 2016, 80, 605-612.	0.7	5
79	Is the ORBIT Bleeding Risk Score Superior to the HAS-BLED Score in Anticoagulated Atrial Fibrillation Patients?. <i>Circulation Journal</i> , 2016, 80, 2102-2108.	0.7	21
80	Assessment of bleeding risk in acute ill medical patients. An essential part of venous thromboembolism prevention. <i>Thrombosis and Haemostasis</i> , 2016, 116, 403-404.	1.8	4
81	Impact of Variations in Kidney Function on Nonvitamin K Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Recent Acute Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 134-140.	0.4	4
82	Von Willebrand factor is associated with atrial fibrillation development in ischaemic patients after cardiac surgery. <i>Europace</i> , 2016, 18, 1328-1334.	0.7	5
83	The SAME-TT2R2score and decision-making between a vitamin K antagonist or a non-vitamin K antagonist oral anticoagulant in patients with atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 177-187.	0.6	18
84	Repercusiones en la posologÃa de los anticoagulantes orales no antagonistas de la vitamina K por las variaciones de la funci3n renal de los pacientes con fibrilaci3n auricular e insuficiencia cardiaca aguda reciente. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 134-140.	0.6	9
85	sST2 levels are associated with all-cause mortality in anticoagulated patients with atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2015, 45, 899-905.	1.7	19
86	Implementation of non-vitamin K antagonist oral anticoagulants in daily practice: the need for comprehensive education for professionals and patients. <i>Thrombosis Journal</i> , 2015, 13, 22.	0.9	37
87	Effects of Body Mass Index on the Lipid Profile and Biomarkers of Inflammation and a Fibrinolytic and Prothrombotic State. <i>Journal of Atherosclerosis and Thrombosis</i> , 2015, 22, 610-617.	0.9	19
88	The importance of excellence in the quality of anticoagulation control whilst taking vitamin K antagonists. <i>Thrombosis and Haemostasis</i> , 2015, 113, 671-673.	1.8	19
89	The SAME-TT2R2 Score Predicts Poor Anticoagulation Control in AF Patients: A Prospective â€œReal-worldâ€™ Inception Cohort Study. <i>American Journal of Medicine</i> , 2015, 128, 1237-1243.	0.6	51
90	Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRs). <i>Europace</i> , 2015, 17, 1197-1214.	0.7	160

#	ARTICLE	IF	CITATIONS
91	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2015, 17, 1467-1507.	0.7	951
92	Comparison of Estimated Glomerular Filtration Rate Equations for Dosing New Oral Anticoagulants in Patients With Atrial Fibrillation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 497-504.	0.4	17
93	GDF-15 and risk stratification in atrial fibrillation. <i>Nature Reviews Cardiology</i> , 2015, 12, 8-9.	6.1	18
94	New Role of Biomarkers in Atrial Fibrillation. , 2015, , 1-33.		1
95	Prognostic role of MIR146A polymorphisms for cardiovascular events in atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2014, 112, 781-788.	1.8	36
96	Usefulness of N-Terminal Pro-B-Type Natriuretic Peptide Levels for Stroke Risk Prediction in Anticoagulated Patients With Atrial Fibrillation. <i>Stroke</i> , 2014, 45, 696-701.	1.0	39
97	Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment. <i>Pharmacogenomics</i> , 2014, 15, 987-996.	0.6	8
98	Novel Oral Anticoagulants in Cardiovascular Disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 34-44.	1.0	23
99	Common Questions in Anticoagulation Management in Atrial Fibrillation. <i>Cardiac Electrophysiology Clinics</i> , 2014, 6, 79-86.	0.7	1
100	SAME-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial Fibrillation. <i>American Journal of Medicine</i> , 2014, 127, 1083-1088.	0.6	112
101	Renal Impairment in a Real-Life Cohort of Anticoagulated Patients With Atrial Fibrillation (Implications for Thromboembolism and Bleeding). <i>American Journal of Cardiology</i> , 2013, 111, 1159-1164.	0.7	110
102	The HAS-BLED Score Has Better Prediction Accuracy for Major Bleeding Than CHADS2 or CHA2DS2-VASc Scores in Anticoagulated Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2199-2204.	1.2	171
103	Atherosclerosis and thromboembolic risk in atrial fibrillation: Focus on peripheral vascular disease. <i>Annals of Medicine</i> , 2013, 45, 274-290.	1.5	25
104	Creating a genotype-based dosing algorithm for acenocoumarol steady dose. <i>Thrombosis and Haemostasis</i> , 2013, 109, 146-153.	1.8	30
105	The prognostic role of the adiponectin levels in atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2013, 43, 168-173.	1.7	20
106	Comparative Determination and Monitoring of Biomarkers of Necrosis and Myocardial Remodeling between Radiofrequency Ablation and Cryoablation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2013, 36, 31-36.	0.5	11
107	Predictive Value of the HAS-BLED and ATRIA Bleeding Scores for the Risk of Serious Bleeding in a Real-World Population With Atrial Fibrillation Receiving Anticoagulant Therapy. <i>Chest</i> , 2013, 143, 179-184.	0.4	176
108	Conventional and New Oral Anticoagulants in the Treatment of Chest Disease and Its Complications. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 413-421.	2.5	5

#	ARTICLE	IF	CITATIONS
109	Oral anticoagulation improves the prognosis of octogenarian patients with atrial fibrillation undergoing percutaneous coronary intervention and stenting. <i>Age and Ageing</i> , 2013, 42, 70-75.	0.7	14
110	Association of the Thrombomodulin Gene c.1418C>T Polymorphism With Thrombomodulin Levels and With Venous Thrombosis Risk. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 1435-1440.	1.1	30
111	Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2013, 110, 1189-1198.	1.8	182
112	Î2-Trace Protein and Prognosis in Patients With Atrial Fibrillation Receiving Anticoagulation Treatment. <i>Chest</i> , 2013, 144, 1564-1570.	0.4	12
113	Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?. <i>Thrombosis and Haemostasis</i> , 2013, 109, 956-960.	1.8	102
114	Novel Associations of VKORC1 Variants with Higher Acenocoumarol Requirements. <i>PLoS ONE</i> , 2013, 8, e64469.	1.1	16
115	Prognostic Value of Mean Platelet Volume in Patients With Non-ST-Elevation Acute Coronary Syndrome. <i>Angiology</i> , 2012, 63, 241-244.	0.8	25
116	Should We Recommend Oral Anticoagulation Therapy in Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting With a High HAS-BLED Bleeding Risk Score?. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 459-466.	1.4	60
117	Dabigatran for the prevention of stroke in atrial fibrillation: is RE-LY reliable?. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1087-1090.	0.9	1
118	Relation of the HAS-BLED Bleeding Risk Score to Major Bleeding, Cardiovascular Events, and Mortality in Anticoagulated Patients With Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 312-318.	2.1	123
119	Edoxaban in Japanese Patients With Nonvalvular Atrial Fibrillation. <i>Circulation Journal</i> , 2012, 76, 1826-1827.	0.7	0
120	High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1500-1507.	1.9	97
121	Predictive Value of the CHA2DS2-VASc Score in Atrial Fibrillation Patients at High Risk for Stroke Despite Oral Anticoagulation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012, 65, 627-633.	0.4	14
122	C0235 Identification of mutations in the protein C gene in a panel of 65 Spanish families with protein C deficiency. <i>Thrombosis Research</i> , 2012, 130, S110-S111.	0.8	0
123	Valor predictivo de la escala CHA2DS2-VASc en pacientes con fibrilaci3n auricular de alto riesgo emb3lico en tratamiento anticoagulante. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 627-633.	0.6	41
124	Ankle brachial index as an independent predictor of mortality in anticoagulated atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2012, 42, 1302-1308.	1.7	21
125	miR-133a Regulates Vitamin K 2,3-Epoxide Reductase Complex Subunit 1 (VKORC1), a Key Protein in the Vitamin K Cycle. <i>Molecular Medicine</i> , 2012, 18, 1466-1472.	1.9	36
126	Oral anticoagulation in chronic kidney disease: A huge challenge. <i>Thrombosis and Haemostasis</i> , 2012, 108, 3-5.	1.8	22

#	ARTICLE	IF	CITATIONS
127	Pro: "Antidote for new anticoagulants" Specific target of inhibition requires a specific target for neutralisation. <i>Thrombosis and Haemostasis</i> , 2012, 108, 621-622.	1.8	5
128	Plasma von Willebrand Factor Levels Are an Independent Risk Factor for Adverse Events Including Mortality and Major Bleeding in Anticoagulated Atrial Fibrillation Patients. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2496-2504.	1.2	121
129	Influence of cardiac resynchronization therapy on indices of inflammation, the prothrombotic state and tissue remodeling in systolic heart failure: A pilot study. <i>Thrombosis Research</i> , 2011, 128, 391-394.	0.8	11
130	Is plasminogen activator inhibitor-1 (PAI-1) a surrogate marker of vascular damage?. <i>Thrombosis Research</i> , 2011, 128, 601-602.	0.8	1
131	An Evaluation of the CHADS 2 Stroke Risk Score in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Revascularization. <i>Chest</i> , 2011, 139, 1402-1409.	0.4	15
132	Study of 18 functional hemostatic polymorphisms in mucocutaneous bleeding disorders. <i>Annals of Hematology</i> , 2010, 89, 1147-1154.	0.8	3
133	Hypouricemic effect of statins: Another pleiotropic benefit?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2010, 139, 1358-1359.	0.4	4
134	Influence of the F12-4 C>T polymorphism on hemostatic tests. <i>Blood Coagulation and Fibrinolysis</i> , 2010, 21, 632-639.	0.5	11
135	Synergism between factor XII "4C>T and factor XIII Val34Leu polymorphisms in fibrinolytic therapy in acute myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2010, 104, 650-652.	1.8	2
136	The additive value of biomarkers to clinical risk scores in acute coronary syndrome. Are biomarkers really ready for real world usage?. <i>Heart</i> , 2010, 96, 227-228.	1.2	11
137	Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk. <i>Annals of Medicine</i> , 2010, 42, 562-575.	1.5	10
138	Deep venous thrombosis or pulmonary embolism and factor V Leiden: enigma or paradox. <i>Haematologica</i> , 2010, 95, 863-866.	1.7	22
139	Effects of atorvastatin 80mg daily on indices of matrix remodelling in "high-risk"™ patients with ischemic heart disease. <i>International Journal of Cardiology</i> , 2010, 139, 95-97.	0.8	6
140	The prognostic value of biomarkers after a premature myocardial infarction. <i>International Journal of Cardiology</i> , 2010, 143, 249-254.	0.8	20
141	Clinical characteristics of patients with factor V Leiden or prothrombin G20210A and a first episode of venous thromboembolism. Findings from the RIETE Registry. <i>Thrombosis Research</i> , 2010, 126, 283-286.	0.8	16
142	CALU A29809G polymorphism in coronary atherothrombosis: Implications for coronary calcification and prognosis. <i>Annals of Medicine</i> , 2010, 42, 439-446.	1.5	12
143	Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis. <i>Thrombosis and Haemostasis</i> , 2009, 101, 483-486.	1.8	37
144	Bone-marrow immunophenotypic analysis allows the identification of high risk of progression and immune condition-related monoclonal gammopathy of undetermined significance. <i>Annals of Medicine</i> , 2009, 41, 547-558.	1.5	4

#	ARTICLE	IF	CITATIONS
145	Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE registry. <i>Thrombosis Research</i> , 2009, 124, 174-177.	0.8	78
146	Influence of electrical cardioversion on inflammation and indexes of structural remodeling, in persistent atrial fibrillation. <i>International Journal of Cardiology</i> , 2009, 132, 227-232.	0.8	13
147	Premature coronary artery disease in young (age < 45) subjects: Interactions of lipid profile, thrombophilic and haemostatic markers. <i>International Journal of Cardiology</i> , 2009, 136, 222-225.	0.8	56
148	Pharmacogenetics in Cardiovascular Antithrombotic Therapy. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1041-1057.	1.2	92
149	Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. <i>Blood</i> , 2009, 113, 4977-4979.	0.6	73
150	Implications of Pharmacogenetics for Oral Anticoagulants Metabolism. <i>Current Drug Metabolism</i> , 2009, 10, 632-642.	0.7	15
151	Premature myocardial infarction: Clinical profile and angiographic findings. <i>International Journal of Cardiology</i> , 2008, 126, 127-129.	0.8	67
152	Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. <i>American Heart Journal</i> , 2008, 156, 85-91.	1.2	80
153	β-glutamyl carboxylase R325Q polymorphism on the response of acenocoumarol. <i>Thrombosis Research</i> , 2008, 122, 429-431.	0.8	4
154	Variables Associated With Contrast-Enhanced Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy: Clinical Implications. <i>Journal of Cardiac Failure</i> , 2008, 14, 414-419.	0.7	33
155	Factor VII -323 decanucleotide D/I polymorphism in atrial fibrillation: Implications for the prothrombotic state and stroke risk. <i>Annals of Medicine</i> , 2008, 40, 553-559.	1.5	14
156	Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis. <i>European Heart Journal</i> , 2008, 30, 139-151.	1.0	74
157	Endothelial protein C receptor polymorphisms and risk of myocardial infarction. <i>Haematologica</i> , 2008, 93, 1358-1363.	1.7	34
158	Letter by Roldan et al Regarding Article, "Plasminogen Activator Inhibitor-1 as a Predictor of Postoperative Atrial Fibrillation After Cardiopulmonary Bypass"; <i>Circulation</i> , 2008, 117, e169; author reply e170.	1.6	0
159	Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation. <i>European Heart Journal</i> , 2008, 30, 932-939.	1.0	44
160	TUBB1 Q43P polymorphism does not protect against acute coronary syndrome and premature myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2008, 100, 1211-1213.	1.8	6
161	Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. <i>Thrombosis and Haemostasis</i> , 2008, 100, 754-755.	1.8	15
162	Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Not for everybody. <i>Thrombosis and Haemostasis</i> , 2008, 100, 754-5.	1.8	3

#	ARTICLE	IF	CITATIONS
163	Plasma angiogenin levels in acute coronary syndromes: implications for prognosis. <i>European Heart Journal</i> , 2007, 28, 3006-3011.	1.0	37
164	Common Carotid Artery Intima-Media Thickness and Intracranial Pulsatility Index in Non-ST-Elevation Acute Coronary Syndromes. <i>Cerebrovascular Diseases</i> , 2007, 24, 338-342.	0.8	11
165	The association of the α 1-tubulin Q43P polymorphism with intracerebral hemorrhage in men. <i>Haematologica</i> , 2007, 92, 513-518.	1.7	38
166	Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. <i>Blood</i> , 2007, 109, 4258-4263.	0.6	104
167	A multimarker risk stratification approach to non-ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro-BNP and fibrin D-dimer levels. <i>Journal of Internal Medicine</i> , 2007, 262, 651-658.	2.7	87
168	Is an advanced age an additive risk factor to the prothrombotic or hypercoagulable state in atrial fibrillation?. <i>International Journal of Cardiology</i> , 2006, 110, 265-266.	0.8	5
169	Antiplatelet versus anticoagulant therapies in advanced age: An unfinished task. <i>International Journal of Cardiology</i> , 2006, 110, 271-272.	0.8	3
170	A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis. <i>Blood</i> , 2006, 108, 177-183.	0.6	58
171	Does smoking status influence the effect of physical exercise on fibrinolytic function in healthy volunteers?. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 21, 163-166.	1.0	4
172	Statins and Postoperative Risk of Atrial Fibrillation Following Coronary Artery Bypass Grafting. <i>American Journal of Cardiology</i> , 2006, 97, 55-60.	0.7	204
173	Effect of Statins on Preventing Recurrence of Atrial Fibrillation After Electrical Cardioversion. <i>American Journal of Cardiology</i> , 2006, 98, 1299-1300.	0.7	23
174	Fluctuations in coagulation activity among patients with atrial fibrillation who are stably anticoagulated. <i>Future Cardiology</i> , 2006, 2, 197-203.	0.5	0
175	Relation of interleukin-6 levels and prothrombin fragment 1+2 to a point-based score for stroke risk in atrial fibrillation. <i>American Journal of Cardiology</i> , 2005, 95, 881-882.	0.7	26
176	Synergistic association between hypercholesterolemia and the C46T factor XII polymorphism for developing premature myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2005, 94, 1294-1299.	1.8	27
177	Pharmacogenetics in Cardiovascular Antithrombotic Therapy. <i>Current Medicinal Chemistry Cardiovascular and Hematological Agents</i> , 2005, 3, 357-364.	1.7	4
178	Influence of smoking habit on cardiac functional capacity and diastolic function in healthy people. <i>International Journal of Cardiology</i> , 2005, 98, 517-518.	0.8	5
179	Are there ethnic differences in the circadian variation in onset of acute myocardial infarction?. <i>International Journal of Cardiology</i> , 2005, 100, 151-154.	0.8	31
180	Correlation of plasma von Willebrand factor levels, an index of endothelial damage/dysfunction, with two point-based stroke risk stratification scores in atrial fibrillation. <i>Thrombosis Research</i> , 2005, 116, 321-325.	0.8	35

#	ARTICLE	IF	CITATIONS
181	Effect of Maximum Dose of Atorvastatin on Inflammation, Thrombogenesis, and Fibrinolysis in High-Risk Patients With Ischemic Heart Disease. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2005, 58, 934-940.	0.4	4
182	A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy for acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2005, 45, 25-29.	1.2	27
183	Five prothrombotic polymorphisms and the prevalence of premature myocardial infarction. <i>Haematologica</i> , 2005, 90, 421-3.	1.7	17
184	Genetic Polymorphisms and Thromboembolic Risk in Atrial Fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2004, 18, 151-152.	1.0	3
185	¿Podemos esperar de los polimorfismos las respuestas a nuestras dudas?. <i>Revista Espanola De Cardiologia</i> , 2004, 57, 1129.	0.6	0
186	Can We Expect Polymorphisms to Answer our Questions?. <i>Revista Espanola De Cardiologia (English Ed)</i> Tj ETQq0 0.0 µgBT /Oerlock 10	0.4	0
187	Matrix metalloproteinases in atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 2004, 43, 152.	1.2	0
188	Factor XIII Val34Leu polymorphism modulates the prothrombotic and inflammatory state associated with atrial fibrillation. <i>Journal of Molecular and Cellular Cardiology</i> , 2004, 37, 699-704.	0.9	36
189	Short alleles of P-selectin glycoprotein ligand-1 protect against premature myocardial infarction. <i>American Heart Journal</i> , 2004, 148, 602-605.	1.2	18
190	Soluble E-selectin, interleukin-6 and tissue factor in two cases of meningococcal septicaemia. <i>Blood Coagulation and Fibrinolysis</i> , 2004, 15, 179-182.	0.5	2
191	Role of factor XIII Val34Leu polymorphism in patients <45 years of age with acute myocardial infarction. <i>American Journal of Cardiology</i> , 2003, 91, 1242-1245.	0.7	25
192	Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. <i>European Heart Journal</i> , 2003, 24, 1373-1380.	1.0	118
193	Fibrinolytic function and atrial fibrillation. <i>Thrombosis Research</i> , 2003, 109, 233-240.	0.8	34
194	Is Thrombogenesis in Atrial Fibrillation Related to Matrix Metalloproteinase-1 and Its Inhibitor, TIMP-1?. <i>Stroke</i> , 2003, 34, 1181-1186.	1.0	93
195	Soluble E-selectin in cardiovascular disease and its risk factors. <i>Thrombosis and Haemostasis</i> , 2003, 90, 1007-1020.	1.8	148
196	Angiogenesis y estatinas, ¿a mayor dosis, mayor beneficio?. <i>Revista Espanola De Cardiologia</i> , 2003, 56, 631-631.	0.6	0
197	Do protein Z levels influence the prothrombotic state in atrial fibrillation?. <i>Thrombosis Research</i> , 2002, 106, 269-270.	0.8	3
198	Diurnal variation of international normalised ratio in patients under oral anticoagulation. <i>Thrombosis Research</i> , 2002, 108, 355.	0.8	0

#	ARTICLE	IF	CITATIONS
199	Prothrombin fragment F1+2 and von Willebrand factor levels and left ventricular systolic function. Peripheral versus intracardiac blood samples. <i>International Journal of Cardiology</i> , 2002, 83, 289-290.	0.8	0
200	Effect of Factor XIII VAL34LEU Polymorphism on Thrombolytic Therapy in Premature Myocardial Infarction. <i>Thrombosis and Haemostasis</i> , 2002, 88, 354-355.	1.8	13
201	Tissue factor/tissue factor pathway inhibitor system and long-term prognosis after acute myocardial infarction. <i>International Journal of Cardiology</i> , 2001, 78, 115-119.	0.8	12
202	Anticoagulant Therapy Modifies Fibrinolytic Dysfunction in Chronic Atrial Fibrillation. Pathophysiology of Haemostasis and Thrombosis: <i>International Journal on Haemostasis and Thrombosis Research</i> , 2000, 30, 219-224.	0.5	3
203	Prothrombotic state and elevated levels of plasminogen activator inhibitor-1 in mitral stenosis with and without atrial fibrillation. <i>American Journal of Cardiology</i> , 1999, 84, 862-864.	0.7	24
204	Hypofibrinolysis in atrial fibrillation. <i>American Heart Journal</i> , 1998, 136, 956-960.	1.2	59